艾司西酞普兰与文拉法辛缓释剂治疗抑郁症的比较研究

A clinical observation of escitalopram and venlafaxine-extended-release(XR) general in the treatment of outpatients with depression

目的:评价和比较艾司西酞普兰与文拉法辛缓释剂治疗抑郁症的临床疗效和安全性。方法:将89例门诊抑郁症患者分别随机给予艾司西酞普兰和文拉法辛缓释剂治疗,在2周内逐步增高剂量至20mg/d或150mg/d,在治疗前后用蒙格马利-阿斯伯格抑郁评定量表(MADRS)、临床整体印象改善评分(CGI)和副反应量表(TESS)评定疗效和不良反应。结果:43例门诊抑郁症患者应用艾司西酞普兰,46例患者应用文拉法辛缓释剂,经治疗后MADRS的总分较治疗前均有统计学差异,第1周时艾司西酞普兰与文拉法辛缓释剂临床缓解率和有效率比较有统计学差异(P<0.01),治疗第8周时艾司西酞普兰与文拉法辛缓释剂临床缓解率分别是51.28%、44.44%;有效率为71.79%、61.11%;两组不良反应轻且发生率少。结论:艾司西酞普兰与文拉法辛缓释剂均能安全、有效地治疗抑郁症。相比而言,艾司西酞普兰起效更快,不良反应较少,可作为门诊治疗抑郁症的首选用药。

AIM：To observe and compare the efficacy and safety of escitalopram and venlafaxine-extended-release（XR） in the treatment of outpatients with depression. METHODS：89 outpatients with depression were randomized to receive escitalopram or venlafaxine-extended-release（XR） for 8 weeks,and dose titrated from 10 mg/d or 75 mg/d to a maximum of 20 mg/d or 150 mg/d respectively within the first 2 weeks of treatment.Effects and adverse events were evaluated with MADRS,HAMA,CGI and TESS before and after the treatment. RESULTS：After 8 weeks treatment,total scores of MADRS of 39 patients with escitalopram or 36 venlafaxine-XR both showed significant change compared with baseline,and escitalopram.After 8 weeks treatment,percentage of recovery were 51.28% and 44.44% respectively,while significant improvement percentage were 71.79% and 61.11% in each group. CONCLUSION：Escitalopram and venlafaxine-extended-release（XR） both are effective and safe antidepressants,and escitalopram has a faster and better effectiveness profile in treatment of depression.